CUV.AX

Equity

CLINUVEL FPO [CUV]

Health Care · Biotechnology

$10.01

+10.01 (+0.00%)

Open

N/A

Day Range

$10.00 - $11.06

52W Range

$9.41 - $14.00

Volume

352K

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Railtown AI Technologies Inc. Announces Closing of $3.4M Fully Subscribed Non-Brokered Private Placement

TMX Newsfile 3 minutes ago

Why Bank of Hawaii (BOH) Shares Are Trading Lower Today

StockStory 6 minutes ago

Medaro Announces Closing of Private Placement

TMX Newsfile 9 minutes ago

Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business

Insider Monkey 9 minutes ago

VTen Announces Closing of Qualifying Transaction and Private Placement

TMX Newsfile 11 minutes ago

Fair Value Estimate

DDM Value

$2.36

324.2% overvalued

Growth: 7.7% | Req. return: 10%

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
ABBV AbbVie Inc. $232.06 N/A 2.87% +0.00%
LLY Eli Lilly and Company $1,052.20 N/A 0.59% +0.00%
NVO Novo Nordisk A/S $37.46 N/A 4.49% +0.00%
EJG.F EBOS Group Ltd. R $11.70 N/A 5.14% +0.00%
5889.T JAPAN EYEWEAR HOLDINGS CO LTD $1,998.00 N/A 4.20% +0.00%
0332.KL TOPVISN $0.17 N/A 11.76% +0.00%
ABT Abbott Laboratories $116.32 N/A 2.06% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About CLINUVEL FPO [CUV]

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

www.clinuvel.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

60

Safe

Based on 4 fundamental factors

+ 7 years of growth

Analysis Tools

Sign in for analysis tools

Share